Biofilm Positivity in Clinical Klebsiella Pneumoniae isolates and Its Associations with Carbapenem Resistance and mrkD, fimH and wcaG Carriage: A Cross-Sectional Study from Egypt
This cross-sectional study of 87 clinical Klebsiella pneumoniae isolates from Egyptian ICUs reveals that carbapenem resistance and the carriage of mrkD, fimH, and wcaG genes are independently associated with a higher likelihood of biofilm formation.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
In the quiet, high-stakes environment of a hospital intensive care unit, a microscopic battle is constantly being waged. The enemy is a bacterium called Klebsiella pneumoniae, a common cause of severe infections like pneumonia and bloodstream infections. For decades, doctors have relied on a powerful class of antibiotics called carbapenems to defeat these invaders when other drugs fail. However, the bacteria are evolving, learning to resist even these last-resort medicines. Complicating matters further is the bacteria's ability to build a protective shield. Much like a fortress wall, this shield is a slimy layer called a biofilm, which the bacteria secrete to stick to surfaces and protect themselves from both antibiotics and the human immune system. When a bacterium can both resist strong drugs and hide behind this biofilm wall, it becomes incredibly difficult to treat, turning a manageable infection into a persistent, life-threatening crisis.
A team of researchers in Egypt recently set out to understand how these two dangerous traits—drug resistance and biofilm building—might be linked. They focused on 87 specific samples of Klebsiella pneumoniae collected from patients in intensive care units at Tanta University Hospitals between January and June 2025. The scientists wanted to see if the bacteria that had learned to resist carbapenems were also the ones most likely to build these protective biofilms. To do this, they first tested the bacteria against a wide range of antibiotics to see which ones could still kill them. They then placed the bacteria in small plastic trays to see if they would stick and form a biofilm layer, measuring how thick and strong that layer became. Finally, they looked inside the bacteria's genetic code to find three specific instruction manuals, or genes, known to help build biofilms: one that helps the bacteria stick to surfaces, another that helps them stick to different types of surfaces, and a third that helps build the sugary material of the biofilm wall.
The results painted a clear and concerning picture. Out of the 87 bacteria tested, more than half were resistant to carbapenems. Among those resistant bacteria, nearly 80 percent were able to form a biofilm, whereas only about 30 percent of the bacteria that were still sensitive to the drugs could do so. The researchers found that the bacteria which built the strongest biofilms were also the ones most likely to be resistant to almost every antibiotic they tested, including the carbapenems. When they looked at the genetic instructions, they found that the bacteria carrying the specific genes for sticking and building walls were much more common in the drug-resistant group. In fact, the presence of these three genes, along with the resistance to carbapenems, each independently increased the likelihood that a bacterium would be a biofilm builder.
This study suggests that in this specific hospital setting, the bacteria that have become resistant to our strongest drugs are also the ones most likely to build protective biofilms. The researchers found that even when they accounted for the presence of the specific genes, the resistance to carbapenems remained strongly linked to the ability to form biofilms. This does not mean that becoming resistant causes the bacteria to build a biofilm, or vice versa; rather, it suggests that these two dangerous traits often travel together in the same bacterial strains. The study was limited to a single hospital and a specific group of patients, so these findings represent a snapshot of a local situation rather than a universal rule. However, the connection is strong enough to warrant attention. It highlights that when doctors face a carbapenem-resistant infection, they are likely also facing a bacterium that has built a fortress around itself, making the infection harder to clear. Understanding this link helps scientists and doctors realize that fighting these superbugs may require new strategies that can break down these biofilm walls, not just kill the bacteria inside them.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.